Market Cap 2.96B
Revenue (ttm) 147.17M
Net Income (ttm) -408.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -277.47%
Debt to Equity Ratio 0.00
Volume 1,079,875
Avg Vol 708,134
Day's Range N/A - N/A
Shares Out 42.92M
Stochastic %K 95%
Beta 3.03
Analysts Sell
Price Target $66.86

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therap...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 833 694 2553
Website: grail.com
Address:
1525 O’Brien Drive, Menlo Park, United States
raleigh_trader
raleigh_trader May. 28 at 2:57 PM
$GRAL back to 100 ladies and gentleman. In from 46$
0 · Reply
LucienW
LucienW May. 28 at 2:30 PM
$TEM $WGS $GRAL any news for the move today?
1 · Reply
HCEarwicker
HCEarwicker May. 28 at 2:28 PM
$GRAL 👀 Beautiful move
0 · Reply
SM07
SM07 May. 28 at 11:02 AM
$GRAL I am sure FDA approval will be granted, but how the SP will react is a ?…🤔
0 · Reply
sam92
sam92 May. 26 at 6:41 PM
$GRAL Volume Today's volume is on track to be heavier than usual, with 669,402 shares having traded so far. The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers. As of 2:37 PM ET Tuesday, 05/26/2026
0 · Reply
sam92
sam92 May. 26 at 6:41 PM
$GRAL Momentum Momentum for GRAL is strongly bullish. The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought. This means that investors have been actively purchasing shares and driving the price higher. As of 2:37 PM ET Tuesday, 05/26/2026
0 · Reply
sam92
sam92 May. 26 at 6:40 PM
$GRAL Trend Analysis GRAL appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.
0 · Reply
FonsieTrader
FonsieTrader May. 26 at 5:36 PM
$GRAL quietly continues building one of the cleaner recovery structures in biotech right now. While everyone chases crowded momentum names… $GRAL keeps printing: → higher lows → steady accumulation → improving momentum → strong reclaim above the 200 MA The chart is starting to look VERY constructive: ✅ trend recovery fully intact ✅ volatility compression after the first expansion ✅ buyers defending every dip ✅ OBV stabilizing again ✅ momentum gradually rebuilding And this is where things get interesting: Biotech momentum can move FAST once institutions rotate back into the sector. Above this current zone: → breakout continuation potential increases sharply → momentum traders likely pile back in → price discovery can accelerate quickly This no longer looks like a dead chart. It’s starting to look like a strong multi-month recovery trend developing underneath the surface. 👀
0 · Reply
WantedToRetireEarly
WantedToRetireEarly May. 23 at 11:45 AM
$GH $GRAL https://finance.yahoo.com/sectors/healthcare/articles/guardant-wins-fda-approval-updated-100000999.html
0 · Reply
JFDI
JFDI May. 22 at 1:32 PM
$GRAL pushing 200d
0 · Reply
Latest News on GRAL
Grail price target lowered to $70 from $82 at Baird

2026-05-07T09:18:38.000Z - 21 days ago

Grail price target lowered to $70 from $82 at Baird


Grail price target raised to $56 from $54 at Piper Sandler

2026-05-07T07:52:29.000Z - 21 days ago

Grail price target raised to $56 from $54 at Piper Sandler


Grail price target raised to $69 from $65 at TD Cowen

2026-05-07T05:21:56.000Z - 21 days ago

Grail price target raised to $69 from $65 at TD Cowen


Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

May 6, 2026, 10:00 AM EDT - 22 days ago

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking


Grail reports Q1 EPS ($2.29), consensus ($1.96)

2026-05-05T20:33:50.000Z - 23 days ago

Grail reports Q1 EPS ($2.29), consensus ($1.96)


GRAIL Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 23 days ago

GRAIL Earnings Call Transcript: Q1 2026


GRAIL Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 23 days ago

GRAIL Earnings release: Q1 2026


GRAIL Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 23 days ago

GRAIL Quarterly report: Q1 2026


GRAIL Reports First Quarter 2026 Financial Results

May 5, 2026, 4:01 PM EDT - 23 days ago

GRAIL Reports First Quarter 2026 Financial Results


GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

GRAIL Proxy statement: Proxy filing


GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

GRAIL Proxy statement: Proxy filing


GRAIL to Announce First Quarter 2026 Financial Results

Apr 22, 2026, 4:01 PM EDT - 5 weeks ago

GRAIL to Announce First Quarter 2026 Financial Results


Grail initiated with a Neutral at Mizuho

2026-04-10T09:55:12.000Z - 6 weeks ago

Grail initiated with a Neutral at Mizuho


Grail initiated with a Neutral at Piper Sandler

2026-04-10T08:45:11.000Z - 6 weeks ago

Grail initiated with a Neutral at Piper Sandler


Grail, Superpower partner to expand early cancer detection

2026-04-01T17:15:43.000Z - 2 months ago

Grail, Superpower partner to expand early cancer detection


Grail price target lowered to $75 from $130 at Guggenheim

2026-03-30T11:54:36.000Z - 2 months ago

Grail price target lowered to $75 from $130 at Guggenheim


Grail upgraded to Buy from Hold at TD Cowen

2026-03-18T09:45:11.000Z - 2 months ago

Grail upgraded to Buy from Hold at TD Cowen


Grail CEO Bob Ragusa to retire, Josh Ofman named successor

Mar 12, 2026, 6:13 PM EDT - 2 months ago

Grail CEO Bob Ragusa to retire, Josh Ofman named successor


Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor

2026-03-12T20:41:38.000Z - 2 months ago

Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor


GRAIL Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 10:30 AM EST - 3 months ago

GRAIL Transcript: TD Cowen 46th Annual Health Care Conference


Grail rises 14.9%

2026-02-24T17:07:19.000Z - 3 months ago

Grail rises 14.9%


Grail price target lowered to $60 from $110 at Morgan Stanley

2026-02-24T12:51:30.000Z - 3 months ago

Grail price target lowered to $60 from $110 at Morgan Stanley


Grail falls -13.5%

2026-02-23T17:06:32.000Z - 3 months ago

Grail falls -13.5%


Grail falls -14.1%

2026-02-23T15:07:00.000Z - 3 months ago

Grail falls -14.1%


Grail falls -47.9%

2026-02-20T17:06:42.000Z - 3 months ago

Grail falls -47.9%


GRAIL Earnings Call Transcript: Q4 2025

Feb 19, 2026, 5:00 PM EST - 3 months ago

GRAIL Earnings Call Transcript: Q4 2025


GRAIL Annual report: Q4 2025

Feb 19, 2026, 5:00 PM EST - 3 months ago

GRAIL Annual report: Q4 2025


GRAIL Earnings release: Q4 2025

Feb 19, 2026, 5:00 PM EST - 3 months ago

GRAIL Earnings release: Q4 2025


A Study on Aging Unlocks Holy Grail of Sports Performance

Jan 26, 2026, 8:00 AM EST - 4 months ago

A Study on Aging Unlocks Holy Grail of Sports Performance


GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 4 months ago

GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference


GRAIL Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 4 months ago

GRAIL Slides: 44th Annual J.P. Morgan Healthcare Conference


Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025

Jan 3, 2026, 10:24 AM EST - 5 months ago

Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025

PL VSAT


Why GRAIL Stock Could Be Biotech's Next Big Breakout

Nov 19, 2025, 10:38 AM EST - 6 months ago

Why GRAIL Stock Could Be Biotech's Next Big Breakout


GRAIL Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 10:00 AM EST - 6 months ago

GRAIL Transcript: Wolfe Research Healthcare Conference 2025


GRAIL Transcript: Analyst Day

Nov 13, 2025, 11:00 AM EST - 7 months ago

GRAIL Transcript: Analyst Day


GRAIL Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

GRAIL Earnings Call Transcript: Q3 2025


GRAIL Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

GRAIL Quarterly report: Q3 2025


GRAIL Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

GRAIL Earnings release: Q3 2025


GRAIL Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:02 PM EST - 7 months ago

GRAIL Reports Third Quarter 2025 Financial Results


GRAIL to Announce Third Quarter 2025 Financial Results

Oct 29, 2025, 4:02 PM EDT - 7 months ago

GRAIL to Announce Third Quarter 2025 Financial Results


GRAIL Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 7 months ago

GRAIL Transcript: Study Result


GRAIL Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 7 months ago

GRAIL Press release: Study Result


GRAIL Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 7 months ago

GRAIL Slides: Study Result


GRAIL, Inc. Announces $325.0 Million Private Placement Financing

Oct 20, 2025, 6:30 AM EDT - 7 months ago

GRAIL, Inc. Announces $325.0 Million Private Placement Financing


What's Happening With GRAIL Stock?

Oct 17, 2025, 9:55 AM EDT - 7 months ago

What's Happening With GRAIL Stock?


GRAIL Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

GRAIL Earnings Call Transcript: Q2 2025


GRAIL Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

GRAIL Quarterly report: Q2 2025


GRAIL Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

GRAIL Earnings release: Q2 2025


GRAIL Slides: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

GRAIL Slides: Q2 2025


GRAIL Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:02 PM EDT - 10 months ago

GRAIL Reports Second Quarter 2025 Financial Results


raleigh_trader
raleigh_trader May. 28 at 2:57 PM
$GRAL back to 100 ladies and gentleman. In from 46$
0 · Reply
LucienW
LucienW May. 28 at 2:30 PM
$TEM $WGS $GRAL any news for the move today?
1 · Reply
HCEarwicker
HCEarwicker May. 28 at 2:28 PM
$GRAL 👀 Beautiful move
0 · Reply
SM07
SM07 May. 28 at 11:02 AM
$GRAL I am sure FDA approval will be granted, but how the SP will react is a ?…🤔
0 · Reply
sam92
sam92 May. 26 at 6:41 PM
$GRAL Volume Today's volume is on track to be heavier than usual, with 669,402 shares having traded so far. The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers. As of 2:37 PM ET Tuesday, 05/26/2026
0 · Reply
sam92
sam92 May. 26 at 6:41 PM
$GRAL Momentum Momentum for GRAL is strongly bullish. The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought. This means that investors have been actively purchasing shares and driving the price higher. As of 2:37 PM ET Tuesday, 05/26/2026
0 · Reply
sam92
sam92 May. 26 at 6:40 PM
$GRAL Trend Analysis GRAL appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.
0 · Reply
FonsieTrader
FonsieTrader May. 26 at 5:36 PM
$GRAL quietly continues building one of the cleaner recovery structures in biotech right now. While everyone chases crowded momentum names… $GRAL keeps printing: → higher lows → steady accumulation → improving momentum → strong reclaim above the 200 MA The chart is starting to look VERY constructive: ✅ trend recovery fully intact ✅ volatility compression after the first expansion ✅ buyers defending every dip ✅ OBV stabilizing again ✅ momentum gradually rebuilding And this is where things get interesting: Biotech momentum can move FAST once institutions rotate back into the sector. Above this current zone: → breakout continuation potential increases sharply → momentum traders likely pile back in → price discovery can accelerate quickly This no longer looks like a dead chart. It’s starting to look like a strong multi-month recovery trend developing underneath the surface. 👀
0 · Reply
WantedToRetireEarly
WantedToRetireEarly May. 23 at 11:45 AM
$GH $GRAL https://finance.yahoo.com/sectors/healthcare/articles/guardant-wins-fda-approval-updated-100000999.html
0 · Reply
JFDI
JFDI May. 22 at 1:32 PM
$GRAL pushing 200d
0 · Reply
DavyDaveCharts
DavyDaveCharts May. 21 at 9:49 PM
$GRAL will this story of weekly imbalances rhyme?
0 · Reply
GoCoogs
GoCoogs May. 21 at 6:18 PM
$GRAL Can we hit $80 heading into ASCO at the end of the month?
1 · Reply
MikeCaymanTrades
MikeCaymanTrades May. 21 at 2:11 AM
$GRAL stock, watch for a bull flag breakout, large upside gap---Weekly chart oversold now moving up. Into the gap now.
0 · Reply
GoCoogs
GoCoogs May. 20 at 11:56 PM
$GRAL 7 million shares are short
0 · Reply
JFDI
JFDI May. 20 at 4:30 PM
$GRAL pretty look
0 · Reply
StockConsultant
StockConsultant May. 20 at 1:51 PM
$GRAL GRAIL stock, watch for a bull flag breakout, large upside gap at https://stockconsultant.com/?GRAL
0 · Reply
DWldn
DWldn May. 17 at 6:03 PM
$GRAL Can see Price reaching for $41.50 if that Daily level of 56.89 doesn't hold on the Daily. So much Liquidity resting below...
0 · Reply
BioTechHealthX
BioTechHealthX May. 17 at 5:43 PM
$GRAL GRAIL’s Galleri test aims to change how cancer is detected, and its latest quarter showed 28% revenue growth and 50% test volume growth. But with heavy losses and clinical data questions, GRAL stock remains one of the most fascinating risky diagnostics plays on the market. https://biotechhealthx.com/biotech-news/is-grail-gral-a-good-stock-to-buy-for-the-future-of-cancer-detection/
0 · Reply
MarketBeat
MarketBeat May. 17 at 4:03 PM
https://marketbeat.com/a/8660044/ $GRAL GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
0 · Reply
BioTechHealthX
BioTechHealthX May. 17 at 10:49 AM
$CDNA $GRAL $NBIX $TNGX $VCYT For investors searching for the best biotech stocks to buy now, these 5 companies offer exposure to diagnostics, rare disease, cancer screening, RNA medicine, and commercial-stage biotech growth. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-climb-as-much-as-100/
0 · Reply
TheUnmaker
TheUnmaker May. 14 at 7:44 PM
$TNXP The volume on these red candles is too damn low! $INBS $HSCS $GRAL
0 · Reply
JFDI
JFDI May. 14 at 7:22 PM
$GRAL in the pocket
0 · Reply